Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CLDN18.2/anti-CD3 bispecific antibody ASP2138

A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CLDN18.2/anti-CD3 bispecific antibody ASP2138 simultaneously binds to both CLDN18.2-expressing tumor cells and CD3-expressing T cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-Claudin18.2/anti-CD3 bispecific antibody ASP2138
anti-Claudin18.2/CD3 bispecific antibody ASP2138
Claudin18.2 x CD3 bispecific antibody ASP2138
Code name:ASP 2138
ASP-2138
ASP2138
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search